866-997-4948(US-Canada Toll Free)

Plasma Cell Neoplasm Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Oct 2012

Category :

Oncology

No. of Pages : 108 Pages


Plasma Cell Neoplasm Pipeline Review, H2 2012

Global Markets Directs, 'Plasma Cell Neoplasm Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Plasma Cell Neoplasm, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Plasma Cell Neoplasm. Plasma Cell Neoplasm Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Plasma Cell Neoplasm.
  • A review of the Plasma Cell Neoplasm products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Plasma Cell Neoplasm pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Plasma Cell Neoplasm.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Plasma Cell Neoplasm pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 7
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Plasma Cell Neoplasm Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Plasma Cell Neoplasm 10
Plasma Cell Neoplasm Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Plasma Cell Neoplasm Therapeutics Products under Investigation by Universities/Institutes 18
Plasma Cell Neoplasm Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
bortezomib - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Lenalidomide + Dexamethasone - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Bryostatin 1 + Vincristine - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
aflibercept - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Natural Killer Cells - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Cyclophosphamide + Fludarabine + Anti-Thymocyte Globulin + Cyclosporine + Peripheral Blood Stem Cell Transplantation + Therapeutic Allogeneic Lymphocytes - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 34
lenalidomide - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Anti-Thymocyte Globulin + Cyclophosphamide + Fludarabine + Peripheral Blood Stem Cell Transplantation - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Anti-Thymocyte globulin + G-CSF + Cyclophosphamide + Fludarabine + Umbilical Cord Blood Transplantation + Methylprednisolone - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 40
G-CSF + Busulfan + Cyclophosphamide + Cyclosporine + Peripheral Stem Cell Transplantation - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
orantinib - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Fludarabine + Cyclophosphamide + Cyclosporine + Allogeneic Lymphocytes + Peripheral Blood Stem Cell Transplantation + Allogeneic Hematopoietic Stem Cell Transplantation + Total Body Irradiation - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 44
Anti-Lymphocyte Globulin + Busulfan + Fludarabine + Allogeneic Hematopoietic Stem Cell Transplantation - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Dexamethasone + Etoposide + Cisplatin + Cyclophosphamide + Filgrastim - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 48
Busulfan + Cyclophosphamide + Stem Cell Transplant + Irradiation - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Cyclophosphamide + Fludarabine Phosphate + Radiation Therapy + Umbilical Cord Blood Transplantation - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Sargramostim + Therapeutic Allogeneic Lymphocytes + Busulfan + Fludarabine Phosphate + Methotrexate + Tacrolimus + Anti-Thymocyte Globulin + Stem Cell Transplantation - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 54
Carmustine + Cyclophosphamide + Etoposide + Autologous Stem Cell Transplantation - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Cyclophosphamide + Total-Body Irradiation + Autologous Stem Cell Transplantation - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Busulfan + Cyclophosphamide + Autologous Stem Cell Transplantation - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Etoposide + Carboplatin + Autologous Stem Cell Transplantation - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Melphalan + Autologous Stem Cell Tranplantation - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Busulfan+ Cyclophosphamide + Autologous Hematopoietic Stem Cell Transplantation - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Busulfan + Fludarabine + Cyclosporine + Mycophenolate Mofetil + Therapeutic Allogeneic Lymphocytes + Granulocyte Colony Stimulating Factor + Phenytoin + Methotrexate + Peripheral Blood Stem Cell Transplantation + Radiation Therapy - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 65
Filgrastim + Cyclophosphamide + Fludarabine + Mycophenolate + Tacrolimus + Radiation Therapy + Allogeneic Bone Marrow Transplantation - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 67
Cyclophosphamide + Anti Thymocyte Globulin + Cyclosporine + Methylprednisolone + Busulphan + G-CSF + Umbilical Cord Blood Transplantation + Radiation Therapy - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Cyclophosphamide + Cyclosporine + Fludarabine Phosphate + Mycophenolate Mofetil + Umbilical Cord Blood Transplantation + Radiation Therapy - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Anti-Thymocyte Globulin + Sargramostim + Therapeutic Allogeneic Lymphocytes + Busulfan + Fludarabine Phosphate + Methotrexate + Tacrolimus - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 73
Busulfan + Fludarabine Phosphate + Cyclosporine A + Mycophenolate Mofetil + Peripheral Stem Cell Transplantation - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 75
Dexamethasone + Etoposide + Cisplatin + Cyclphosphamide + Filgrastim + Thalidomide - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 77
Dexamethasone + Etoposide + Cisplatin + Cyclphosphamide + Filgrastim + Thalidomide - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 79
Peripheral Blood Lymphocyte Therapy + Mycophenolate Mofetil + Tacrolimus + Allogeneic Bone Marrow Transplantation + Radiation Therapy - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 81
Therapeutic Allogeneic Lymphocytes + Cyclophosphamide + Cyclosporine + Fludarabine Phosphate + Tacrolimus + Radiation Therapy + Peripheral Blood Stem Cell Allotransplantation - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 83
Anti-Thymocyte Globulin + Busulfan + Cyclophosphamide + Fludarabine + Methotrexate + Tacrolimus + Allogeneic Peripheral Blood Progenitor Cell Transplantation - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 85
Rituximab + Fludarabine + Etoposide + Doxorubicin + Vincristine + Cyclophosphamide + Prednisone + Filgrastim + Cytarabine + Cyclosporine + Allogeneic Stem Cell Transplantation + Donor Lymphocyte Infusion - Drug Profile 86
Product Description 86
Mechanism of Action 87
R&D Progress 88
Anti-Thymocyte Globulin + G-CSF + Busulfan + Cyclophosphamide + Cyclosporine + Methylprednisolone + Umbilical Cord Blood Transplantation + Radiation Therapy - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 91
Anti-Thymocyte Globulin + Graft-Versus-Tumor Induction Therapy + Fludarabine Phosphate + Melphalan + Allogeneic Stem Cell Transplantation + Total Body Irradiation - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 93
Anti-Thymocyte Globulin + Graft-Versus-Tumor Induction Therapy + GM-CSF + Therapeutic Allogeneic Lymphocytes + Cyclophosphamide + Fludarabine + Methylprednisolone + Mycophenolate Mofetil + Tacrolimus + Allogeneic Peripheral Blood Stem Cell Transplantation + Peripheral Stem Cell Transplantation + Umbilical Cord Blood Transplantation - Drug Profile 94
Product Description 94
Mechanism of Action 95
R&D Progress 96
Anti-Thymocyte Globulin + Cyclophosphamide + Cyclosporine + Fludarabine + Mycophenolate + Methylprednisolone + Allopurinol + Filgrastim + Peripheral Blood Stem Cell Transplantation + Radiation Therapy - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 98
Cyclophosphamide + Bone Marrow Transplantation - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Bortezomib + Liposomal Doxorubicin + Dexamethasone - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Carfilzomib + Melphalan + Filgrastim - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Plasma Cell Neoplasm Therapeutics Drug Profile Updates 102
Plasma Cell Neoplasm Therapeutics Discontinued Products 104
Plasma Cell Neoplasm Therapeutics - Dormant Products 105

Appendix 107
Methodology 107
Coverage 107
Secondary Research 107
Primary Research 107
Expert Panel Validation 107
Contact Us 108
Disclaimer 108

List of Table


Number of Products Under Development for Plasma Cell Neoplasm, H2 2012 10
Products under Development for Plasma Cell Neoplasm Comparative Analysis, H2 2012 11
Number of Products under Investigation by Universities/Institutes, H2 2012 13
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 14
Comparative Analysis by Late Stage Development, H2 2012 15
Comparative Analysis by Mid Clinical Stage Development, H2 2012 16
Comparative Analysis by Early Clinical Stage Development, H2 2012 17
Products under Investigation by Universities/Institutes, H2 2012 18
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 26
Plasma Cell Neoplasm Therapeutics Drug Profile Updates 102
Plasma Cell Neoplasm Therapeutics Discontinued Products 104
Plasma Cell Neoplasm Therapeutics Dormant Products 105

List of Chart


Number of Products under Development for Plasma Cell Neoplasm, H2 2012 10
Products under Development for Plasma Cell Neoplasm Comparative Analysis, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 12
Late Stage Products, H2 2012 15
Mid Clinical Stage Products, H2 2012 16
Early Clinical Stage Products, H2 2012 17
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Route of Administration, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Molecule Type, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 26

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *